No results for ‘’
Kilitch Drugs (India) Ltd
₹183.80
(5.41%)
Mon, 25 May 2026, 10:10 pm
Health Technology
Pharmaceuticals: Major
24.5KKilitch Drugs (India) Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 31.43 | 27.16 | 12.66 | 8.15 | 13.92 | 7.72 | 1.16 | 8.40 | 21.29 | 0 | 0 | 0 | 21.71 | 75.76 | 148.82 | 34.18 | 35.43 | 20.81 | 42.53 | 21.77 |
| Price to book ratio | 1.14 | 2.28 | 2.78 | 1.41 | 1.88 | 0.94 | 0.70 | 0.23 | 0.21 | 0.30 | 0.43 | 0.60 | 0.97 | 2.51 | 1.06 | 0.98 | 1.88 | 1.43 | 3.56 | 2.87 |
| Price to sales ratio | 0.54 | 0.96 | 1.22 | 0.70 | 1 | 0.55 | 0.82 | 0.86 | 1.77 | 1.97 | 2.28 | 22.19 | 2.20 | 3.52 | 2.35 | 1.83 | 2.29 | 1.56 | 4.02 | 2.93 |
| Price to cash flow ratio | 1.60 | 1.82 | 0 | 8.55 | 9.15 | 4.31 | 0 | 2.85 | 0 | 0 | 2.54 | 582.67 | 66.12 | 418.14 | 31.18 | 2.78 | 43.28 | 0 | 0 | 42.95 |
| Enterprise value | 211.25M | 500.35M | 1.81B | 1.26B | 1.83B | 1.26B | -507.6M | -836.56M | -579.42M | 64.74M | 206.09M | 5.77B | 784.69M | 2.65B | 1.1B | 937.17M | 2.25B | 1.79B | 5.83B | 5.69B |
| Enterprise value to EBITDA ratio | 29.30 | 9.82 | 7.86 | 5.26 | 7.66 | 5.65 | -4.10 | 0 | 0 | 0 | 0 | 1010 | 13 | 31.97 | 161.92 | 16.72 | 19.68 | 9.93 | 23.59 | 17.72 |
| Debt to equity ratio | 0.69 | 1.46 | 0.83 | 0.55 | 0.58 | 0.63 | 0.08 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.08 | 0.11 | 0.12 | 0.15 | 0.15 | 0.18 | 0.24 |
| Return on equity % | 0 | 9.06 | 34.88 | 19.26 | 15.45 | 13.23 | 76.75 | 2.81 | 0.98 | -0.24 | -9.79 | -8.47 | 4.91 | 3.29 | 0.70 | 2.99 | 5.53 | 7.19 | 8.91 | 14.10 |
Kilitch Drugs (India) Ltd Enterprise Value
The Kilitch Drugs (India) Ltd Enterprise Value is a key financial metric used by investors to evaluate Kilitch Drugs (India) Ltd's valuation, profitability, and overall financial performance. Tracking the Kilitch Drugs (India) Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Kilitch Drugs (India) Ltd (NSE: KILITCH, BSE: 524500) is currently trading at ₹183.80, with a market capitalization of ₹6.09B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Kilitch Drugs (India) Ltd Enterprise Value is essential for fundamental analysis.
Kilitch Drugs (India) Ltd Enterprise Value Current Value
The current Kilitch Drugs (India) Ltd Enterprise Value stands at 5.69B.
The Kilitch Drugs (India) Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Kilitch Drugs (India) Ltd Enterprise Value Historical Trend
The Kilitch Drugs (India) Ltd Enterprise Value has shown the following historical trend:
- 2024: 5.69B
- 2023: 5.83B
- 2022: 1.79B
- 2021: 2.25B
- 2020: 937.17M
The decline in Kilitch Drugs (India) Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Kilitch Drugs (India) Ltd Enterprise Value Indicates for Investors
The Kilitch Drugs (India) Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Kilitch Drugs (India) Ltd.
Kilitch Drugs (India) Ltd Enterprise Value Analysis Summary
The Kilitch Drugs (India) Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Kilitch Drugs (India) Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Kilitch Drugs (India) Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.